

ARCTIC AURORA LIFESCIENCE

Capturing value from global healthcare innovation

REASONS TO INVEST




Exposure to global companies with focus on innovation




Specialised investment team



Long-term growth potential



Top 5 positions



AUM	NOK 2,230m
Start date	25.11.2016
Reference index	MSCI World Pharma / Biotech / Life Science
Fund type	Equity fund (UCITS)
SFDR	Article 8
PRIIP Risk class (1-7)	4
Management fee	1.25% p.a.
Performance fee	15% p.a.
Portfolio managers:	Ulrica Slåne Bjerke Torbjørn Bjerke Daniel Bolanowski
Analyst	Mark Fábíán

INVESTMENT APPROACH


The fund invests in the most innovative biotech and pharma companies developing new treatments that significantly change the life of patients to the benefit of society.

The investment team has a deep understanding of biotech and pharma as industries and investment fields.

The team has regular contact with company management teams and contacts are followed up closely.

The fund do not invest in early-stage biotech prior to clinical development in patients.

The fund has delivered 97 % return since inception



The fund focuses on big pharma and emerging biotech

